Notwithstanding encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from managed care entities. These companies are often building barriers to access, including high cost restrictions and approval processes that hinder consumer access. Indus… Read More